A Decade of Gadolinium Retention and Deposition: ESMRMB-GREC Insights

Overview

Gadolinium-based contrast agents (GBCA) have been widely used in MRI since 1988, with over 750 million doses administered. Evidence shows that linear GBCA can lead to gadolinium deposition in brain regions such as the dentate nucleus and globus pallidus, with retention influenced by GBCA stability and patient renal function.

Background

GBCA enhance MRI image contrast by shortening tissue T1 and T2 relaxation times via paramagnetic gadolinium ions tightly bound in chelates to prevent toxicity. Linear and macrocyclic ligands differ in their stability and propensity for gadolinium release. Gadolinium deposition in the brain was first reported in 2014, linked primarily to repeated administrations of linear GBCA. Understanding GBCA physicochemistry, transmetallation, and elimination kinetics is essential to assess deposition risks.

Data Highlights

Key Findings

• Gadolinium deposition in the brain primarily occurs with repeated use of linear extracellular GBCA, especially in the dentate nucleus and globus pallidus.
• Macrocyclic GBCA exhibit higher thermodynamic and kinetic stability, resulting in less gadolinium retention and faster elimination.
• Gadolinium ions can dissociate from linear GBCA via transmetallation with endogenous metal ions, potentially forming insoluble toxic compounds.
• Renal impairment prolongs GBCA elimination half-life, increasing the risk of gadolinium release and deposition.
• Gadolinium deposition is also observed in other brain regions and the anterior pituitary gland, which lacks a blood-brain barrier.
• Preclinical animal studies confirm dose-dependent gadolinium retention independent of age or sex, with long-term retention preferentially in the dentate nucleus.

Clinical Implications

Clinicians should consider the type of GBCA used, favoring macrocyclic agents to minimize gadolinium retention, especially in patients requiring multiple contrast-enhanced MRI scans. Renal function assessment is critical prior to GBCA administration to reduce prolonged exposure and potential deposition. Awareness of gadolinium retention sites may inform imaging interpretation and patient monitoring.

Conclusion

Over the past decade, evidence has established that gadolinium retention in the brain is predominantly associated with linear GBCA use, with macrocyclic agents demonstrating improved safety profiles. Ongoing research and careful clinical use are essential to mitigate deposition risks while maintaining diagnostic efficacy.

References

1. Bayer AG estimates 2023 -- GBCA usage data
2. Kanda et al. 2014 -- Gadolinium deposition in brain MRI
3. European group 2014 -- Gadolinium retention in MS patients
4. Preclinical studies 2011-2020 -- Gadolinium retention animal models